tbuckley/cabot-search huggingface dataset:
AB0413 Systemic Therapy in Primary Sjögren Syndrome Patients
Authors: M. Fernandez Castro, J.L. Andreu, C. Sanchez-Piedra, V. Martinez Taboada, A. Olive, J. Rosas
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Primary Sjögren syndrome (pSS) is a systemic autoimmune disease involving mainly the exocrine glandular system. Nevertheless, its clinical spectrum includes the development of multiple extra-glandular manifestations which will be determinant for the use of systemic therapy. <h3>Objectives</h3> The aim of our study was to describe the systemic therapy in a pSS cohort assisted in Spanish Rheumatology Departments and its association with the involvement of different organs. <h3>Methods</h3> This is a multicenter descriptive transversal study of pSS patients fulfilling European/American consensus criteria. Patients were included by randomization from thirty-three Rheumatology departments. Data were collected by reviewing clinical records and interviewing the patients. Informed consent was obtained and local ethics committees approved the study. Variables were analysed by descriptive statistical methods, using means, medians, and rates. Chi-square was used to establish the statistical associations, being considered a p&lt;0,05 as significant. <h3>Results</h3> Four hundred and thirty-seven patients were included. Ninety-five percent of them were women. The median age of the cohort was 58 years. Eighty-four percent of the patients have been treated (currently or previously) with non-steroidal anti-inflammatory drugs (NSAID), 49% had been treated with glucocorticoids (GC), 7% with boluses of GC, 51% with antimalarial, 13% with methotrexate (MTX), 10% with azathioprine (AZA), 4% with mycophenolate mofetil (MM) and 3% with cyclophosphamide (CF). NSAIDs were significantly used more frequently in patients with joint involvement. GC were significantly used more frequently in patients with joint, pulmonary, central and peripheral nervous system (CNS and PNS) involvement and cytopenia. GC boluses were used significantly more frequently in patients with musculoskeletal, pulmonary and nervous system involvement. Antimalarials were significantly used more frequently in patients with joint involvement. MTX was significantly used more frequently in patients with joint, CNS involvement and cytopenia. AZA was significantly used more frequently in patients with lung and CNS involvement and cytopenia. MM was significantly used more frequently in patients with renal, lung and PNS involvement, and cytopenia. CF was significantly used more frequently in patients with joint, pulmonary, CNS and PNS involvement. <h3>Conclusions</h3> Despite the absence of clinical controlled studies demonstrating efficacy and safety, systemic therapy use in SSp patients is very frequent. Its use is mainly associated with the presence of musculoskeletal, neurological, pulmonary and haematological manifestations. <h3>Disclosure of Interest</h3> None declared
Integration of Minimal Residual Disease with Other Patient Risk Factors Identifies a Population with Very Poor Overall Survival in Pediatric ALL: Results from the UKALL 2003 Trial
Authors: David O'Connor, Jack Bartram, Amir Enshaei, Anthony V Moorman, Christine Harrison, Rachel Wade, Rachel Clack, Jeremy Hancock, Sujith Samarasinghe, John Moppett, Ajay J. Vora, Nicholas Goulden
Journal: Blood (2015)
Molecular Response According to Type of Preexisting BCR-ABL Mutations after Second Line Dasatinib Therapy in Chronic Phase CML Patients.
Authors: Martin C. Mueller, Philipp Erben, Thomas Ernst, Michelle Giehl, Thomas Schenk, Jana Hoffmann, Stephanie Lauber, Jens Kruth, Benjamin Hanfstein, Eric Bleickardt, Claude Nicaise, Rüdiger Hehlmann, Andreas Hochhaus
Journal: Blood (2007)
Antagonizing IAPs by SMAC Mimetic TL32711 Induces Apoptosis in AML Cells Including AML Stem/Progenitor Cells Alone and in Combination with Chemotherapy
Authors: Bing Z Carter, Duncan H Mak, Yihua Qiu, Steven M. Kornblau, Po Yee Mak, David Weng, Mark A McKinlay, Michael Andreeff
Journal: Blood (2011)
P0835 : German multicenter cohort on sofosbuvir-based treatments in HCV mono- and HIV/HCV co-infected patients (GECOSO)
Authors: P. Ingiliz, S. Christensen, D. Hueppe, T. Lutz, K. Schewe, C. Boesecke, K.G. Simon, G. Schmutz, A. Baumgarten, H. Busch, S. Mauss
Journal: Journal of Hepatology (2015)
Reduction of Relapse Incidence and Improvement of Leukemia Free Survival by Allogeneic Stem Cell Transplantation in Patients with AML and Normal Karyotype Irrespective of the FLT3-ITD Status.
Authors: Frank Schueler, Nadezda Basara, Georg Maschmeyer, Thomas Fischer, Michael Herold, Herbert G. Sayer, Hans-Heinrich Wolf, Ute Kreibich, Detlev Haehling, Gottfried Doelken, Christian Junghanss, Norbert Grobe, Rainer Krahl, Haifa Kathrin Al-Ali, Wolfram Poenisch, Dietger Niederwieser
Journal: Blood (2009)
Tumor Cell Dissemination and Tissue Infiltration Are Associated with CXCL12-G801A Polymorphism in De Novo Acute Myeloid Leukemia.
Authors: Olivier Herault, Florence Dommange, Claire Espanel, Jorge Domenech, Lotfi Benboubker, Marc Ohresser, Philippe Colombat, Christian Binet, Herve Watier, Guillaume Cartron
Journal: Blood (2004)
The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis
Authors: Mariola Kurowska-Stolarska, Manhl K. Hasoo, David J. Welsh, Lynn Stewart, Donna McIntyre, Brian E. Morton, Steven Johnstone, Ashley M. Miller, Darren L. Asquith, Neal L. Millar, Ann B. Millar, Carol A. Feghali-Bostwick, Nikhil Hirani, Peter J. Crick, Yuqin Wang, William J. Griffiths, Iain B. McInnes, Charles McSharry
Journal: Journal of Allergy and Clinical Immunology (2016)

BackgroundIdiopathic pulmonary fibrosis (IPF) is progressive and rapidly fatal. Improved understanding of pathogenesis is required to prosper novel therapeutics. Epigenetic changes contribute to IPF; therefore, microRNAs may reveal novel pathogenic pathways.ObjectivesWe sought to determine the regulatory role of microRNA (miR)-155 in the profibrotic function of murine lung macrophages and fibroblasts, IPF lung fibroblasts, and its contribution to experimental pulmonary fibrosis.MethodsBleomycin-induced lung fibrosis in wild-type and miR-155−/− mice was analyzed by histology, collagen, and profibrotic gene expression. Mechanisms were identified by in silico and molecular approaches and validated in mouse lung fibroblasts and macrophages, and in IPF lung fibroblasts, using loss-and-gain of function assays, and in vivo using specific inhibitors.ResultsmiR-155−/− mice developed exacerbated lung fibrosis, increased collagen deposition, collagen 1 and 3 mRNA expression, TGF-β production, and activation of alternatively activated macrophages, contributed by deregulation of the miR-155 target gene the liver X receptor (LXR)α in lung fibroblasts and macrophages. Inhibition of LXRα in experimental lung fibrosis and in IPF lung fibroblasts reduced the exacerbated fibrotic response. Similarly, enforced expression of miR-155 reduced the profibrotic phenotype of IPF and miR-155−/− fibroblasts.ConclusionsWe describe herein a molecular pathway comprising miR-155 and its epigenetic LXRα target that when deregulated enables pathogenic pulmonary fibrosis. Manipulation of the miR-155/LXR pathway may have therapeutic potential for IPF.Graphical abstract
P0264 : Redirecting adenovirus-specific T cells by a tumor-specific T cell receptor for therapy of hepatocellular carcinoma
Authors: C.I. Ureche, E. Guerlevik, N. Woller, B. Fleischmann-Mundt, A. Kloos, M.P. Manns, S. Kubicka, F. Kuehnel
Journal: Journal of Hepatology (2015)
Divergence in CD19-Mediated Signaling Unfolds Intra-Clonal Diversity in Chronic Lymphocytic Leukemia Which Correlates with Disease Progression
Authors: Yair Herishanu, Sigi Kay, Nili Dezorella, Chava Perry, Varda Deutsch, Aaron Polliack, Elizabeth Naparstek, Benzion Katz
Journal: Blood (2012)
Consistency, Replication, and Meta-analyses of Altered Brain Activity in Unipolar Depression
Authors: Deanna M. Barch, David Pagliaccio
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
AB0490 Plasma Vitamin D Level in Primary Sjogren's Syndrome – Tunisian Comparative Study of 66 Patients
Authors: M. Tougorti, A. Kallel, M.K. Ben fradj, I. Ben Ghorbel, M. Feki, J. Riadh, M.H. Houman, N. Kaabechi
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Beyond its critical function in calcium homeostasis, vitamin D has recently been found to play an important role in the modulation of the immune/inflammation system. Increasing numbers of study have established that vitamin D insufficiency contributes to a number of diseases, suggesting a range of physiological functions of vitamin D. Recent findings seem to show that low vitamin D levels in patients with Sjogren Syndrom could be associated with severe complications such as peripheral neuropathy. <h3>Objectives</h3> The purpose of this study was to evaluate plasma vitamin D level in Primary Sjogren9s Syndrome (PSS) and comparing it with healthy controls. <h3>Methods</h3> North Africans patients (Tunisian patients) with PSS were diagnosed in an internal medicine department. All patients with PSS meet the revised AECG criteria 2002 and/or ACR proposed criteria 2012. We proceed in this prospective study with a comparison of plasma vitamin D between two groups, with a matched age and sex, one of patients with a Primary Sjogren9s Syndrome (PSS) and a second of healthy control subjects. Sixty six patients with PSS were enrolled. Sex ratio was 0.11 (59 female (89.4%) and 7 male (10.6%)).Mean age at diagnosis was 49.07 years ±12.56 (range 26 -73years). Forty eight healthy controls were included. Sex ratio was 0, 14 (42 females (87.5%) and 6 males (12.5%). Registration and statistical analysis of data were done with SPSS. Plasma 25-hydroxyvitamin D (25-OHD) concentrations were measured by a competitive chemiluminescence immunoassay using the Liaison Analyzer (DiaSorin Inc., Stillwater, MN). The inter-assay CV was below 10%. Vitamin D deficiency was defined according to the most recent cut-points defined by The Institute of Medicine as 25-OHD concentrations &lt;10 μg/L. <h3>Results</h3> Plasma vitamin D level of PSS patients was insufficient in 42.2% of cases (plasma vitamin D level &lt;30 μg/L) and in 57.8% of cases plasma vitamin D level was lower than 10 μg/L. Plasma vitamin D was lower than 10 μg/L in 66.66% of healthy controls. There is no significant variation of plasma vitamin D levels according to sex, in the PSS group. Plasma vitamin D levels are not significantly decreased in patients with central and/or peripheral neurological manifestations compared to patients with no neurological symptoms. Plasma vitamin D levels are, however; significantly lower in male patients than controls. <h3>Conclusions</h3> The incidence of vitamin D deficiency seems more important for PSS patients than healthy controls. It might be interesting to study these patients to examine the outcome of the disease and its severity after a vitamin D supplementation therapy. <h3>Disclosure of Interest</h3> None declared
Ruxolitinib Efficacy and Safety in Myelofibrosis: A Multicenter Observational Study
Authors: Damianos Sotiropoulos, Vassilios Papadopoulos, Maria Dimou, Despoina Kyriakou, George Papaioannou, George Karavalakis, Emmanuel Papadakis, Maria Palasopoulou, Anastasia Banti, Taxiarchis Kourelis, Alexandra Kouraklis, Theodoros Marinakis, Nora-Athina Viniou, Eleftheria Hatzimichael, Diamantina Vasilatou, George Vassilopoulos, Panayiotis Panayiotidis, Achilles Anagnostopoulos
Journal: Blood (2015)
P-Glycoprotein Is Related to the Achievement of Complete Remission but Not to Disease-Free Survival in Adult Acute Lymphoblastic Leukemia: A Prospective Analysis in the JALSG-ALL97 Study.
Authors: Akihiro Takeshita, Kazunori Ohnishi, Yasushi Miyazaki, Itsuro Jnnai, Shuichi Miyawaki, Masatomo Takahashi, Toru Murakami, Nobumasa Inoue, Junji Tanaka, Norio Asou, Yukio Kobayashi, Ryuzo Ueda, Ryuzo Ohno
Journal: Blood (2004)
Gene Therapy of Chronic Myelogenous Leukemia Using Pseudotyped Recombinant Adeno-Associated Viral Vectors.
Authors: Leopold Sellner, Marlon R Veldwijk, Jürgen A. Kleinschmidt, Stephanie Laufs, Julian Topaly, W. Jens Zeller, Frederik Wenz, Stefan Fruehauf
Journal: Blood (2009)
THU0453 High Prevalence of Psoriatic Arthritis Misdiagnoses in Psoriasis Patients in Russian Dermatological Clinics Based on Psoriasis Epidemiology Screening Tool (PEST), Rheumatological Evaluation and The Caspar Criteria
Authors: M. Chamurlieva, T. Korotaeva, E. Loginova
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> According to official Russian Federation statistics the mean annual incidence of psoriatic arthritis (PsA) in patients (pts) with psoriasis (PsO) is 2.5%. Lower estimates may reflect a missed diagnosis of PsA. The efficiency of PsA screening approach in PsO pts in Russian dermatological clinics remains unknown. <h3>Objectives</h3> to evaluate the prevalence and misdianosis of PsA in PsO pts in dermatological clinics according to the PEST questionnaire, rheumatological evaluation and the CASPAR criteria. <h3>Methods</h3> 103 consecitive unselected pts (male-47/female-56) with plaque PsO mean age 44±13.69 years (yrs.), BSA 9.32±13.55%, PASI 15.39 ± 12.51, DQLI 9.42±6.8 with no known diagnosis of inflammatory arthritis were included. All pts completed the PEST questionnaire before being consulted by a dermatologist. A total score PEST≥3 is indicative of PsA, PEST&lt;3 is non-PsA. All pts were subsequently evaluated by a rheumatologist to confirm/exclude PsA. The CASPAR criteria are considered to be the "gold standard" for the diagnosis of PsA. The sensitivity (Sen.) and the specificity (Sp.) of the PEST, (%) were calculated. <h3>Results</h3> 60 out of 103 pts (58.2%) had PEST≥3 but after rheumatological assessment according to the CASPAR criteria PsA confirmed in significantly fewer cases – in 47 out of 60 pts (78.3%) and in 13 out of 60 pts (21.6%) PsA was overdiagnosed (false-positive). 43 out of 103 pts (63.4%) had PEST&lt;3 but even so in 14 out of 43 pts (32.5%) PsA was undiagnosed and then confirmed after rheumatological assessment according to the CASPAR criteria (false-negative). So finally the prevalence of PsA in a series of 103 plaque PsO pts was 59.2% (61 pts). PsA was misdiagnosed in 27 out of 103 pts (26.2%). PEST Sen./Sp. were 77%/69% accordingly. <h3>Conclusions</h3> In dermatological clinics the PEST questionnaire is a proper approach that is available for PsA screening. But PEST alone is limited due to high amounts of misdiagnoses. All pts should follow up with a rheumatologist and the CASPAR criteria despite the PEST results. For proper diagnosis of PsA among PsO pts need interdisciplinary collaboration with rheumatologists. <h3>Disclosure of Interest</h3> None declared
Clinical and Biological Prognostic Factors Evaluation of Diffuse Large B-Cell Lymphoma Patients Relapsed or Refractory After Previous Line with Rituximab Plus Chemotherapy. Results of the Study PRO-R-IPI (NCT01369784),
Authors: Carlos Panizo, Anny Jaramillo, Gonzalo Gutierrez-Garcia, Francisco Javier Díaz, Eva González-Barca, Raquel de Oña, Nerea Castro, Juan Manuel Sancho, María Flor García-Alvarez, Blanca Sanchez-Gonzalez, Francisco Javier Peñalver, Jimena Cannata-Ortiz, Manuel Espeso, María José Requena, Santiago Gardella, Soledad Durán, Ana Pilar González-Rodríguez, Ricardo García-Muñoz, Maurizio Bendandi, Dolores Caballero
Journal: Blood (2011)
Immunomodulatory Drugs Are Efficacious Against Primary Effusion Lymphoma By Targeting IKZF1, IRF4 and MYC in a CRBN-Dependent Manner and Are Synergistic with BRD4 Inhibitors
Authors: Ramakrishnan Gopalakrishnan, Hittu Matta, Bhairavi Tolani, Timothy Junius Triche, Preet Chaudhary
Journal: Blood (2014)
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy
Authors: Trevor J. Cunningham, Mary Tabacchi, Jean-Pierre Eliane, Sara Moradi Tuchayi, Sindhu Manivasagam, Hengameh Mirzaalian, Ahu Turkoz, Raphael Kopan, Andras Schaffer, Arturo P. Saavedra, Michael Wallendorf, Lynn A. Cornelius, Shadmehr Demehri
Journal: Journal of Clinical Investigation (2016)

Actinic keratosis is a precursor to cutaneous squamous cell carcinoma. Long treatment durations and severe side effects have limited the efficacy of current actinic keratosis treatments. Thymic stromal lymphopoietin (TSLP) is an epithelium-derived cytokine that induces a robust antitumor immunity in barrier-defective skin. Here, we investigated the efficacy of calcipotriol, a topical TSLP inducer, in combination with 5-fluorouracil (5-FU) as an immunotherapy for actinic keratosis.The mechanism of calcipotriol action against skin carcinogenesis was examined in genetically engineered mouse models. The efficacy and safety of 0.005% calcipotriol ointment combined with 5% 5-FU cream were compared with Vaseline plus 5-FU for the field treatment of actinic keratosis in a randomized, double-blind clinical trial involving 131 participants. The assigned treatment was self-applied to the entirety of the qualified anatomical sites (face, scalp, and upper extremities) twice daily for 4 consecutive days. The percentage of reduction in the number of actinic keratoses (primary outcome), local skin reactions, and immune activation parameters were assessed.Calcipotriol suppressed skin cancer development in mice in a TSLP-dependent manner. Four-day application of calcipotriol plus 5-FU versus Vaseline plus 5-FU led to an 87.8% versus 26.3% mean reduction in the number of actinic keratoses in participants (P < 0.0001). Importantly, calcipotriol plus 5-FU treatment induced TSLP, HLA class II, and natural killer cell group 2D (NKG2D) ligand expression in the lesional keratinocytes associated with a marked CD4+ T cell infiltration, which peaked on days 10-11 after treatment, without pain, crusting, or ulceration.Our findings demonstrate the synergistic effects of calcipotriol and 5-FU treatment in optimally activating a CD4+ T cell-mediated immunity against actinic keratoses and, potentially, cancers of the skin and other organs.ClinicalTrials.gov NCT02019355.Not applicable (investigator-initiated clinical trial).
Delayed Platelet Engraftment after Umbilical Cord Blood Transplant: Relationship to Circulating Levels of Thrombopoietin
Authors: Karen K. Ballen, Shuli Li, Corey S Cutler, Yi-Bin Chen, Steven L. McAfee, Bimalangshu R Dey, Maria Theresa Le, Karen M. Winkfield, David Avigan, Jacalyn Rosenblatt, Robin Joyce, Vassiliki A Boussiotis, Vincent T. Ho, Philippe Armand, Edwin P. Alyea, John Koreth, Robert J Soiffer, Thomas R. Spitzer, Joseph H. Antin, Robert Makar, David J. Kuter
Journal: Blood (2014)
Post-Transplant Outcome in Patients with Acute Myeloid Leukemia and Myelodysplasic Syndrome Who Received Conditioning Regimen Based On Fludarabin, Busulfan and Anti-Thymoglobulin Prior to Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Claire Oudin, Patrice Chevallier, Sabine Furst, Thierry Guillaume, Jean El Cheikh, Roberto Crocchiolo, Jacques Delaunay, Anne Etienne, Norbert Vey, Mohamad Mohty, Didier Blaise
Journal: Blood (2012)
AB0713 Spectrum of Atlantoaxial Ankylosis (AAA) in The Ankylosing Spondylitis (AS): Is It Really Chronological Changes That Occur with Disease Progression or Are There Two Completely Different Pathways?
Authors: S. Lee, T.-H. Kim, Y. Song, Y.B. Joo, J.-B. Jun
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The morphologic characteristics of atlantoaxial ankylosis in AS patient and suggests different pathways of involvement resulting in atlantoaxial subluxation in AS patients <h3>Objectives</h3> To evaluate morphologic characteristics of AAA in AS patient and classify them into categories which reflects the end-stage manifestations of two differents disease pathways. <h3>Methods</h3> Plain radiographs of cervical spine in 62 AS patients with AAA were reviewed. We classified AAA in AS patients into three subtypes: loss of atlantodental interval (type I), ankylosis of facet joint (type II) and ankylosis of anterior longitudinal ligament or anterior atlantooccipital membrane with cervical spine (type III). And then, we categorized 62 AS patients with AAA into two subgroups: group A (21 patients) with only synovial joint involvement of AS (type I or type II or both) and group B (41 patients) with enthesis involvement of AS with additional synovial joint involvement (type III plus type I or type II or both). We compared the results of mSASSS and disease duration between group A and B. <h3>Results</h3> The mean cervical mSASSS of patients in group A and B were 27.3 and 16.0 each (p value, 0.196). The mean duration of AS patients in group A and B were 23.7 and 23.6 years each. There was no siginificant differences in cervical, lumbar and total mSASSS or disease duration between the two groups. <h3>Conclusions</h3> We propose that atlantoaxial joint involvement in the AS patients is not chronological changes that occur with disease progression, but rather it is end-stage manifestation of two different pathways: one only involving synovial joint and the other one involving both synovial joint and enthesis. <h3>References</h3> Martel W. The occipito-atlanto-axial joints in rheumatoid arthritis and ankylosing spondylitis. Am J Roentgenol Radium Ther Nucl Med 1961;86:223–240 Meijers KA, van Voss SF, Francois RJ. Radiological changes in the cervical spine in ankylosing spondylitis. Ann Rheum Dis1968;27:333–338 Lee HS, Kim TH, Yun HR, Park YW, Jung SS, Bae SC, et al. Radiologic changes of cervical spine in ankylosing spondylitis.Clin Rheumatol 2001;20:262–266 Laiho K, Kauppi M. The cervical spine in patients with ankylosing spondylitis. Clin Exp Rheumatol 2002;20:738 <h3>Disclosure of Interest</h3> None declared
L-Asparaginase (L-ASP) Related Toxicities with Asparaginase Erwinia Chrysanthemi in a Large Compassionate Use Protocol.
Authors: Paul V. Plourde, Sima Jeha, Nobuko Hijiya, Frank G Keller, Susan R. Rheingold, Zoann E. Dreyer, Gary V. Dahl, Taheri Mercedes, Tim Corn
Journal: Blood (2012)